Axess Health | Blog

Novartis named SA’s no.1 employer in pharmaceutical industry

Written by Novartis | Feb 24, 2023 12:01:38 PM

Being certified as a Top Employer showcases an organisation’s dedication to a better world of work and exhibits this through excellent HR policies and people practices. 

“We are honoured to have received this recognition, especially at a time when the world of work has changed fundamentally. With the pandemic dramatically accelerating the pace of change and profoundly reshaping working models, Novartis has been intentional about being mindful of the general well-being of our employees whilst ensuring growth and personal development,” says Sibonile Dube, Head of Communications and Engagement, Middle East and Africa for Novartis.

The Top Employers Institute programme certifies organisations based on the participation and results of their HR Best Practices Survey. This survey covers six HR domains consisting of 20 topics including People Strategy, Work Environment, Talent Acquisition, Learning, Diversity, Equity & Inclusion, Well-being and more.   

Top Employers Institute CEO David Plink says: “Exceptional times bring out the best in people and organisations. And we have witnessed this in our Top Employers Certification Programme this year: exceptional performance from the certified Top Employers 2023. These employers have always shown that they care for the development and well-being of their people. By doing so, they collectively enrich the world of work.” 

The programme has certified and recognized 2,053 Top Employers in 121 countries or regions across five continents. 

“At Novartis, we believe that our employees are the key to our success, and we are dedicated to investing in their growth and development. As a company focused on developing innovative medicines, this strategy has ensured that we also apply an ethos of innovation internally, drawing on the latest well-being and performance science to nurture our staff and transform our working environment,” says Dube. 

 Media release from Novartis